Juvenal Tobin W 4

What Happened

• Juvenal Tobin, Chief Commercial Officer of Castle Biosciences (CSTL), exercised stock options on 2026-05-21 to acquire 11,210 common shares by paying $3.38 per share for a total cash outlay of $37,890. The filing also shows the corresponding disposition of the derivative instrument (the option) at $0 consideration, reflecting cancellation/ conversion of the option.

Key Details

• Transaction date: 2026-05-21
• Action: Option exercise (Form 4 code M)
• Shares acquired: 11,210 at $3.38 each; total paid = $37,890
• Related entry: 11,210 underlying option units reported as disposed at $0 (represents the option’s conversion/cancellation)
• Vesting note: Footnote F1 states the options were fully vested
• Shares owned after transaction: not disclosed in the provided excerpt
• Timeliness: Filing shows the report date 2026-05-26 for a 2026-05-21 transaction (filed late); late Form 4s reduce near-term transparency but are routinely corrected

Context

• This was an exercise of vested options, not an open-market purchase or sale of existing shares. The record does not show any immediate open-market sale of the shares received. The disposition line at $0 is standard bookkeeping on Form 4 to show the option instrument was extinguished when converted into shares.